Presence of Hepatitis B Surface Antibody in Addition to Hepatitis B Core Antibody Confers Protection Against Hepatitis B Virus Infection in Hepatitis B Surface Antigen–negative Patients Undergoing Kidney Transplantation
Jae Wan Jeon,So Mi Kim,Hyungjin Cho,Chung Hee Baek,Hyosang Kim,Sung Shin,Young Hoon Kim,Duck Jong Han,Soon Bae Kim,Kim, So Mi,Shin, Sung,Cho, Hyungjin,Han, Duck Jong,Kim, Soon Bae,Kim, Young Hoon,Jeon, Jae Wan,Baek, Chung Hee,Kim, Hyosang
DOI: https://doi.org/10.1097/TP.0000000000002173
2019-10-03
Transplantation
Abstract:Background
The American Gastroenterological Association and European Association for the Study of the Liver recommend that hepatitis B surface antigen (HBsAg)–negative and hepatitis B core antibody (anti-HBc)–positive patients who receive immunosuppression should be monitored for hepatitis B virus (HBV) infection regardless of hepatitis B surface antibody (anti-HBs) status. However, anti-HBs may provide protection against infection. To investigate whether the presence of anti-HBs in addition to anti-HBc confers protection, we classified HBsAg(−) kidney transplantation (KT) patients into 4 groups according to anti-HBc and anti-HBs status, and compared the HBV infection rate between the anti-HBc(+)anti-HBs(+) group and the other 3 groups.
Methods
In this single-center retrospective study, we classified 1959 patients into 4 groups: anti-HBc(−)anti-HBs(−) (n = 356), anti-HBc(−)anti-HBs(+) (n = 652), anti-HBc(+)anti-HBs(−) (n = 142), and anti-HBc(+)anti-HBs(+) (n = 809).
Results
Hepatitis B virus infection was noted in 31 (1.6%) patients after KT. There was a significant difference in HBV infection rate between anti-HBc(+)anti-HBs(+) (1.2%) and anti-HBc(+)anti-HBs(−) (5.6%) (P < 0.001), but not between anti-HBc(+)anti-HBs(+) and anti-HBc(−)anti-HBs(−) (1.1%) or anti-HBc(−)anti-HBs(+) (1.4%). There was a significant difference in HBV infection rate according to anti-HBs titer, but no difference according to the donor viral profile. Hepatic failure occurred in 1 anti-HBc(+)anti-HBs(−) patient and 1 anti-HBc(+)anti-HBs(+) patient, both of whom died. Hepatocellular carcinoma was noted in 4 anti-HBc(−) patients, but not in anti-HBc(+) patients.
Conclusions
The presence of anti-HBs confers protection against HBV infection. We recommend monitoring for HBV infection after KT in HBsAg(−) anti-HBc(+) anti-HBs(−) patients, but not in HBsAg(−) anti-HBc(+) anti-HBs(+) patients.
immunology,surgery,transplantation